{
    "clinical_study": {
        "@rank": "46917", 
        "acronym": "IAB2M", 
        "arm_group": {
            "arm_group_label": "[89Zr]Df-IAB2M", 
            "arm_group_type": "Experimental", 
            "description": "A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional)."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I/IIa  study evaluating the safety and feasibility of [89Zr]Df-IAB2M as an\n      immunoPET tracer for metastatic prostate cancer. Individuals participating in this study\n      will have a FDG PET scan, as well as four (4) PET scans (over a 3 day period) following the\n      injection of [89Zr]Df-IAB2M PET tracer. Three different dosing levels will be explored. The\n      purpose of the study is to demonstrate the safety of [89Zr]Df-IAB2M, ability to detect\n      prostate cancer, and optimal time point and dose level for imaging."
        }, 
        "brief_title": "Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "IAB2M is an approximately 80 kDA molecular weight antibody fragment (a \"Minibody\"). Limited\n      (Phase 0/Proof-of-concept) patient experience with this biologic targeting agent has been\n      previously obtained with SPECT imaging Ex-US, demonstrating targeting of soft tissue and\n      bone lesions in advanced metastatic prostate cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male >/= 18 years of age\n\n          -  Patients with histologically confirmed prostate cancer\n\n          -  Progressive disease manifest (within 6 weeks of screening) by either\n\n               -  imaging modalities (bone scan, MRI or CT) OR\n\n               -  biochemical progression (PSA)\n\n          -  Performance status of 60 or higher on Karnofsky scale\n\n          -  Subject's schedule permits compliance with all study procedures\n\n          -  Ability to understand and willingness to sign a written informed consent form\n\n        Exclusion Criteria:\n\n          -  Previous anaphylactic reaction to huJ591 antibody or FDG imaging\n\n          -  On any new anticancer therapy (GnRH analog allowed) while on the study\n\n          -  Hepatic lab values: Bilirubin>1.5 ULN; AST/ALT >2.5 ULN; Albumin < 2 g/dL; GGT > 2.5\n             ULN if Alkaline Phostphatase >2.5 ULN\n\n          -  Renal lab values:  Creatinine > 1.5 ULN\n\n          -  Other severe acute or chronic medical condition that may increase the risk associated\n             with study participation or investigational product administration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923727", 
            "org_study_id": "002-2012"
        }, 
        "intervention": {
            "arm_group_label": "[89Zr]Df-IAB2M", 
            "intervention_name": "[89Zr]Df-IAB2M", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "[89Zr]Df-IAB2M", 
            "Prostate", 
            "PET Scan"
        ], 
        "lastchanged_date": "August 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer", 
        "other_outcome": {
            "description": "Evaluate the biodistribution of [89Zr]Df-IAB2M with PET/CT scans, whole body counts and blood samples to determine the radiation dose to organs in individuals with metastatic prostate cancer.", 
            "measure": "Determine the radiation dose levels from a single infusion of [89Zr]Df-IAB2M in individuals with metastatic prostate cancer", 
            "safety_issue": "No", 
            "time_frame": "Day 1 (Infusion Visit) to Day 3"
        }, 
        "overall_contact": {
            "email": "pandit-n@mskcc.org", 
            "last_name": "Neeta Pandit-Taskar, MD", 
            "phone": "212-639-7372"
        }, 
        "overall_contact_backup": {
            "email": "morrism@mskcc.org", 
            "last_name": "Michael Morris, MD", 
            "phone": "646-422-4469"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Neeta Pandit-Taskar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To assess the safety of a single dose of of [89Zr]Df-IAB2M", 
                "measure": "Determine the safety of [89Zr]Df-IAB2M PET in patients with metastatic prostate cancer.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (Infusion Day) through Day 7"
            }, 
            {
                "description": "Imaging, whole body count and blood samples will be used for standard biodistribution and PK analysis.", 
                "measure": "Evaluate biodistribution and PK of [89Zr]Df-IAB2M PET/CT scans for visual detection of metastatic prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Infusion Day) to Day 3"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923727"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the ability of 89Zr-Df-IAb2M PET to detect known sites of disease in patients with metastatic prostate cancer", 
                "measure": "[89Zr]Dr-IAB2M PET/CT quantitative assessment of metastatic prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Infusion Day) to Day 3"
            }, 
            {
                "description": "To evaluate the mass dose and hours post infusion that provides optimal detection of metastatic prostate cancer", 
                "measure": "Optimal parameters for imaging with [89Zr]Df-IAB2M", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Infusion Day) to Day 3"
            }, 
            {
                "description": "To compare the results of the biopsy and FDG PET scan to the [89Zr]Df-IAB2M images", 
                "measure": "Sensitivity of [89Zr]Df-IAB2M to detect metastatic prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }
        ], 
        "source": "ImaginAb, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ImaginAb, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}